CTOs on the Move

Mediant Health Resources

www.medianthealthcare.com

 
Mediant Health Resources is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Cunningham Drug Co Inc

Cunningham Drug Co Inc is a New Tazewell, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tapinator

Tapinator (Ticker: TAPM) is a global developer and publisher of mobile games on the iOS, Google Play, and Amazon platforms. The Company focuses on operating its own titles, publishing properties where it holds substantial ownership positions, and making strategic investments into promising mobile companies. Tapinator’s owned and operated portfolio includes over 55 mobile gaming titles that, collectively, have over 30 million users. A number of these titles have risen to the top of the mobile leaderboard charts and have been featured by the Apple, Google, and Amazon App Stores. Founded in 2013, Tapinator is headquartered in New York, with development offices in Pakistan, Denmark and Indonesia.

Transcend Services

Transcend Services, Inc. (Transcend) provides medical transcription services to the healthcare industry. The Company provides two primary medical transcription options for customers: the provision of transcription services and technology using the

Fulcrum Health

Leveraging physical medicine to transform health care.

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.